Key result
A 63-year-old female patient with atrial fibrillation developed a spontaneous hemothorax while receiving 15 mg once daily rivaroxaban therapy.
Why the study?
Although new oral anticoagulants have better compliance and safety margin compared to warfarin, caution is needed regarding potential complications such as spontaneous hemothorax.
Case Report (n=1)
No
This case report highlights a rare but severe bleeding complication (spontaneous hemothorax) associated with rivaroxaban use.
Spontaneous hemothorax may occur with rivaroxaban in AF; this single case leaves open questions on rare bleeding incidence.
New oral anticoagulants have emerged as an alternative for warfarin for thromboembolic prevention in patients with nonvalvular atrial fibrillation. Although new oral anticoagulants have better compliance and safety margin compared to warfarin, we must be cautious with their usage. In this article, we report a case of spontaneous hemothorax related to rivaroxaban treatment. According to our research, this is the first case of spontaneous hemothorax secondary to rivaroxaban treatment.
No takes yet. Share an insight, caveat, or question.
İbrahim Yıldız (2019) conducted a case report in Spontaneous hemothorax (n=1). Rivaroxaban was evaluated. A 63-year-old female patient with atrial fibrillation developed a spontaneous hemothorax while receiving 15 mg once daily rivaroxaban therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: